Market: NASD |
Currency: USD
Address: 1065 East Hillsdale Boulevard
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Show more
📈 Terns Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$17.20
-
Upside/Downside from Analyst Target:
148.20%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-13
-
EPS Estimate:
-0.29
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Terns Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2025-11-12 (estimated upcoming) | - |
| 2025-08-05 | -0.26 |
| 2025-05-08 | -0.26 |
| 2025-03-20 | -0.24 |
| 2024-11-12 | -0.28 |
| 2024-08-05 | -0.31 |
| 2024-05-13 | -0.3 |
| 2024-03-14 | -0.29 |
| 2023-11-14 | -0.42 |
| 2023-08-08 | -0.25 |
| 2023-05-15 | -0.31 |
| 2023-03-27 | -0.29 |
| 2022-11-09 | -0.44 |
| 2022-08-08 | -0.55 |
| 2022-05-16 | -0.55 |
| 2022-03-03 | -0.56 |
| 2021-11-15 | -0.47 |
| 2021-08-16 | -0.43 |
| 2021-05-13 | -0.88 |
| 2021-03-30 | -0.03 |
📰 Related News & Research
No related articles found for "terns pharmaceuticals".
